User profiles for Ilias Gountas

Ilias Gountas

Verified email at med.uoa.gr
Cited by 4049

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

…, J García-Samaniego, AG Khan, I Gountas… - The lancet …, 2017 - thelancet.com
Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the …

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

…, J Genov, J Gerstoft, A Goldis, I Gountas… - The lancet …, 2018 - thelancet.com
Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (…

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

…, J Gerstoft, L Gheorghe, A Goldis, I Gountas… - The lancet …, 2017 - thelancet.com
Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and
mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting …

Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high‐prevalence setting?

I Gountas, V Sypsa, O Anagnostou, N Martin… - …, 2017 - Wiley Online Library
Aims To project the impact of scaling‐up oral anti‐viral therapy and harm reduction on chronic
hepatitis C (CHC) prevalence and incidence among people who inject drugs (PWID) in …

[HTML][HTML] HCV elimination among people who inject drugs. Modelling pre-and post–WHO elimination era

I Gountas, V Sypsa, S Blach, H Razavi, A Hatzakis - PloS one, 2018 - journals.plos.org
Background Elimination of hepatitis C virus (HCV) among people who inject drugs (PWID) is
a costly investment, so strategies should not only focus on eliminating the disease, but also …

[HTML][HTML] Impact of the COVID-19 pandemic on HPV vaccinations in Switzerland and Greece: road to recovery

I Gountas, A Favre-Bulle, K Saxena, J Wilcock… - Vaccines, 2023 - mdpi.com
The COVID-19 pandemic has caused significant disruptions to healthcare, including reduced
administration of routinely recommended HPV vaccines in a number of European countries…

Act early, save lives: managing COVID-19 in Greece

I Gountas, G Hillas, K Souliotis - Public health, 2020 - Elsevier
Objectives The aim of the study was to assess the impact of social distancing interventions
in Greece and to examine what would have happened if those interventions had not been …

[HTML][HTML] Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals

I Gountas, V Sypsa, G Papatheodoridis… - World Journal of …, 2019 - ncbi.nlm.nih.gov
BACKGROUND Hepatitis C virus (HCV) is a leading cause of worldwide liver-related morbidity
and mortality. The World Health Organization released an integrated strategy targeting …

[HTML][HTML] Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

…, I Gountas, E Duffell, K Gountas… - The Lancet Regional …, 2024 - thelancet.com
Background Epidemiological data are crucial to monitoring progress towards the 2030
Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic …

[HTML][HTML] Could the 2010 HIV outbreak in Athens, Greece have been prevented? A mathematical modeling study

I Gountas, G Nikolopoulos, G Touloumi, A Fotiou… - Plos one, 2021 - journals.plos.org
Introduction In 2009 and 2010, Athens, Greece experienced a hepatitis C virus (HCV) and a
Human Immunodeficiency Virus (HIV) outbreak among People Who Inject Drugs (PWID), …